Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,356 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
AQP4-IgG-seronegative patient outcomes in the N-MOmentum trial of inebilizumab in neuromyelitis optica spectrum disorder.
Marignier R, Pittock SJ, Paul F, Kim HJ, Bennett JL, Weinshenker BG, Wingerchuk DM, Green AJ, Fujihara K, Cutter G, Aktas O, Hartung HP, Drappa J, Ratchford JN, She D, Smith M, Rees W, Cimbora D, Katz E, Cree BAC; N-MOmentum study investigators. Marignier R, et al. Among authors: katz e. Mult Scler Relat Disord. 2022 Jan;57:103356. doi: 10.1016/j.msard.2021.103356. Epub 2021 Nov 1. Mult Scler Relat Disord. 2022. PMID: 35158465 Free article. Clinical Trial.
Placebo-controlled study in neuromyelitis optica-Ethical and design considerations.
Cree BA, Bennett JL, Sheehan M, Cohen J, Hartung HP, Aktas O, Kim HJ, Paul F, Pittock S, Weinshenker B, Wingerchuk D, Fujihara K, Cutter G, Patra K, Flor A, Barron G, Madani S, Ratchford JN, Katz E. Cree BA, et al. Among authors: katz e. Mult Scler. 2016 Jun;22(7):862-72. doi: 10.1177/1352458515620934. Epub 2015 Dec 14. Mult Scler. 2016. PMID: 26666258 Free PMC article. Clinical Trial.
Safety and tolerability of an anti-CD19 monoclonal antibody, MEDI-551, in subjects with systemic sclerosis: a phase I, randomized, placebo-controlled, escalating single-dose study.
Schiopu E, Chatterjee S, Hsu V, Flor A, Cimbora D, Patra K, Yao W, Li J, Streicher K, McKeever K, White B, Katz E, Drappa J, Sweeny S, Herbst R. Schiopu E, et al. Among authors: katz e. Arthritis Res Ther. 2016 Jun 7;18(1):131. doi: 10.1186/s13075-016-1021-2. Arthritis Res Ther. 2016. PMID: 27267753 Free PMC article. Clinical Trial.
Safety and tolerability of inebilizumab (MEDI-551), an anti-CD19 monoclonal antibody, in patients with relapsing forms of multiple sclerosis: Results from a phase 1 randomised, placebo-controlled, escalating intravenous and subcutaneous dose study.
Agius MA, Klodowska-Duda G, Maciejowski M, Potemkowski A, Li J, Patra K, Wesley J, Madani S, Barron G, Katz E, Flor A. Agius MA, et al. Among authors: katz e. Mult Scler. 2019 Feb;25(2):235-245. doi: 10.1177/1352458517740641. Epub 2017 Nov 16. Mult Scler. 2019. PMID: 29143550 Free PMC article. Clinical Trial.
Neuromyelitis optica spectrum disorder: Patient experience and quality of life.
Beekman J, Keisler A, Pedraza O, Haramura M, Gianella-Borradori A, Katz E, Ratchford JN, Barron G, Cook LJ, Behne JM, Blaschke TF, Smith TJ, Yeaman MR. Beekman J, et al. Among authors: katz e. Neurol Neuroimmunol Neuroinflamm. 2019 Jun 20;6(4):e580. doi: 10.1212/NXI.0000000000000580. eCollection 2019 Jul. Neurol Neuroimmunol Neuroinflamm. 2019. PMID: 31355316 Free PMC article.
Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trial.
Cree BAC, Bennett JL, Kim HJ, Weinshenker BG, Pittock SJ, Wingerchuk DM, Fujihara K, Paul F, Cutter GR, Marignier R, Green AJ, Aktas O, Hartung HP, Lublin FD, Drappa J, Barron G, Madani S, Ratchford JN, She D, Cimbora D, Katz E; N-MOmentum study investigators. Cree BAC, et al. Among authors: katz e. Lancet. 2019 Oct 12;394(10206):1352-1363. doi: 10.1016/S0140-6736(19)31817-3. Epub 2019 Sep 5. Lancet. 2019. PMID: 31495497 Clinical Trial.
Neuromyelitis optica spectrum disorder in China: Quality of life and medical care experience.
Huang W, ZhangBao J, Chang X, Wang L, Zhao C, Lu J, Wang M, Ding X, Xu Y, Zhou L, Li D, Behne MK, Behne JM, Yeaman MR, Katz E, Lu C, Quan C; Guthy-Jackson Charitable Foundation International Clinical Consortium (GJCF-ICC). Huang W, et al. Among authors: katz e. Mult Scler Relat Disord. 2020 Nov;46:102542. doi: 10.1016/j.msard.2020.102542. Epub 2020 Sep 29. Mult Scler Relat Disord. 2020. PMID: 33296965
Sensitivity analysis of the primary endpoint from the N-MOmentum study of inebilizumab in NMOSD.
Cree BA, Bennett JL, Kim HJ, Weinshenker BG, Pittock SJ, Wingerchuk D, Fujihara K, Paul F, Cutter GR, Marignier R, Green AJ, Aktas O, Hartung HP, Williams IM, Drappa J, She D, Cimbora D, Rees W, Ratchford JN, Katz E. Cree BA, et al. Among authors: katz e. Mult Scler. 2021 Nov;27(13):2052-2061. doi: 10.1177/1352458521988926. Epub 2021 Feb 4. Mult Scler. 2021. PMID: 33538237 Free PMC article. Clinical Trial.
1,356 results